Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3408608 | 0.90 | CA2 (0.47) | CA2CA1CA7CA5ACA5B | |
| SCHEMBL3410737 | 0.81 | KCNA5 (0.54) | CA2CA1CA7CA5ACA5B | |
| SCHEMBL17495247 | 0.79 | L3MBTL1 (0.54) | KMT2AKCNA5MAPTSMN1; SMN2LIN28A | |
| SCHEMBL30097972 | 0.79 | L3MBTL1 (0.54) | KMT2AKCNA5MAPTSMN1; SMN2LIN28A | |
| SCHEMBL18157925 | 0.78 | SMN1; SMN2 (0.59) | KMT2AKCNA5MAPTSMN1; SMN2LIN28A | |
| SCHEMBL29777383 | 0.78 | SMN1; SMN2 (0.59) | KMT2AKCNA5MAPTSMN1; SMN2LIN28A | |
| SCHEMBL2830314 | 0.77 | MAPT (0.55) | CA2CA1CA7CA5ACA5B | |
| SCHEMBL3404054 | 0.76 | CA2 (0.65) | CA2CA1CA7CA5ACA5B | |
| SCHEMBL18741270 | 0.76 | KMT2A (0.50) | KMT2AMAPTSMN1; SMN2LIN28ATDP1 | |
| SCHEMBL15489522 | 0.76 | CYP2C19 (0.55) | KMT2AKCNA5MAPTSMN1; SMN2LIN28A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2823826-A2 | Inhibitors of carbonic anhydrase IX | Molecular Insight Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2823826-A2 | Inhibitors of carbonic anhydrase IX | Molecular Insight Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877970-B2 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2240171-B1 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARM INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2240171-B1 | Inhibitors of carbonic anhydrase IX | MOLECULAR INSIGHT PHARM INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2240171-A2 | INHIBITORS OF CARBONIC ANHYDRASE IX | Molecular Insight Pharmaceuticals, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009089383-A2 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089383-A2 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | CA9, CA12, CA1 | CA2 7/4885CA1 3/4885CA7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.